Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | ME2 | P23368 | 1/20 | 0.43 |
| ▸ | ME1 | P48163 | 1/20 | 0.43 |
| ▸ | ME3 | Q16798 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20214639 | 0.90 | ENPP2 (0.52) | NPC1KMT2ARAB9AUSP2GAA | |
| SCHEMBL22915949 | 0.88 | NPC1 (0.51) | NPC1KMT2AL3MBTL1ALDH1A1ME2 | |
| SCHEMBL6421007 | 0.83 | TRPV1 (0.52) | ENPP2TSHR | |
| SCHEMBL6423786 | 0.82 | CACNA2D1 (0.47) | — | |
| SCHEMBL6421762 | 0.81 | KDR (0.49) | NPC1KMT2ARAB9AGAAPTGDR2 | |
| SCHEMBL22915890 | 0.80 | KDM4E (0.47) | KDM4E | |
| SCHEMBL4154205 | 0.80 | ENPP2 (0.36) | NPC1RAB9AKDM4EENPP2 | |
| SCHEMBL15492450 | 0.80 | CREBBP (0.47) | NPC1RAB9AKDM4EENPP2EP300 | |
| SCHEMBL1994788 | 0.79 | NAMPT (0.38) | KDM4EENPP2EP300 | |
| SCHEMBL22915917 | 0.79 | MEN1 (0.51) | NPC1KMT2ARAB9AGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2021-11-30 | — | — | US | disclosed |
| EP-3548613-B1 | BACTERIAL GLUTAMINYL CYCLASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PERIODONTITIS | FRAUNHOFER GES FORSCHUNG (DE) | 2021-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | GMPS, QPCT, GLS | NPC1 3805/4885KMT2A 3341/4885RAB9A 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.